reports
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Progra...
Achieve Life Sciences Announces Data from Cytisinicline ORCA-V1 Program to be Presented at Society of General Internal Medicine (SGIM) Annual Meeting SEATTLE and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced data from the Phase 2 ORCA-V1 vaping cessation trial will be presented today, Friday, May 17, 2024, at the Society of General Internal Medicine (SGIM) An...
Achieve Life Sciences Reports Financial Results for First Quarter 2024...
Achieve Life Sciences Reports Financial Results for First Quarter 2024 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Thursday, May 9, 2024 SEATTLE and VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced its financial results for the first quarter of 2024 and provided an update on the cytisinicline development program. Rece...
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Ce...
Achieve Life Sciences Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine Phase 2 ORCA-V1 trial showed treatment with cytisinicline more than doubled odds of quitting e-cigarettes compared with placebo Cytisinicline treatment well tolerated with no serious adverse events reported and excellent compliance to study treatment Achieve expects to conduct an End-of-Phase 2 Meeting with the FDA later this year to discuss Phase 3 trial plans SEATTLE and VANCOUVER, British Columbia, May 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasda...
Achieve Life Sciences to Announce First Quarter Financial Results and ...
Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 9, 2024 SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast...
Achieve Life Sciences to Present at Life Science Innovation Northwest ...
Achieve Life Sciences to Present at Life Science Innovation Northwest 2024 Conference SEATTLE and VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will present at the Life Science Innovation Northwest (LSINW) 2024 Conference being held at the Seattle Convention Center April 17-18, 2024. The Achieve corporate presentation w...
Achieve Life Sciences Reports Financial Results for Fourth Quarter and...
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2023 and Provides Corporate Update Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 SEATTLE and VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced fourth quarter and year-end 2023 financial results and provided an update on the cytisinicline developmen...
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program t...
Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT) Annual Meeting SEATTLE and VANCOUVER, British Columbia, March 20, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that three oral presentations featuring data from both of the Phase 3 ORCA-2 and ORCA-3 clinical trials of cytisinicline for smoking cess...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Fin...
Achieve Life Sciences to Announce Fourth Quarter and Year-End 2023 Financial Results and Host Conference Call and Webcast on March 28, 2024 SEATTLE and VANCOUVER, British Columbia, March 14, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its fourth quarter and year-end 2023 financial results and provide an update on the cytisinicline development program on Thursday, March 28, 2024,...
Achieve Life Sciences Announces Participation at Upcoming Investor Con...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences. John Bencich, CEO of Achieve, will be presenting and participating in a live panel at the Life Sciences Investor Forum to be ...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cyti...
Achieve Life Sciences Reaches Agreement with the FDA on Long-Term Cytisinicline Exposure Data Requirements for NDA Submission Open-label exposure trial expected to initiate in Q2’24 with NDA filing anticipated in 1H 2025 SEATTLE and VANCOUVER, British Columbia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) ...
Achieve Life Sciences Announces Pricing of up to $124.2 Million Regist...
Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement $60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds to conduct clinical development of cytisinicline through New Drug Application submission expected in 1H 2025, including the ORCA-OL trial Aggregate net proceeds (assuming exercise of all milestone-driven warrants) expected to be sufficient to fund cytisinicline development through potential FDA approval SEATTLE, Wa...
Achieve Life Sciences Announces Participation at Upcoming Investor Con...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences SEATTLE and VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences. John Bencich, CEO of Achieve, will be presenting and participating in a live panel at the Life Sciences Investor Forum to be hel...
Achieve Life Sciences Reports Financial Results for Third Quarter and ...
Achieve Life Sciences Reports Financial Results for Third Quarter and Provides Corporate Update Company to host conference call at 4:30 PM EST today, Thursday, November 9, 2023 SEATTLE and VANCOUVER, British Columbia, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced third quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Business High...
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results...
Achieve Life Sciences to Announce Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 9, 2023 SEATTLE and VANCOUVER, British Columbia, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its third quarter 2023 financial results and provide an update on the cytisinicline development program on Thursday, November 9, 2023 at 4:30 PM EST. ...
Achieve Life Sciences Announces Participation at Upcoming Investor Con...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences SEATTLE and VANCOUVER, British Columbia, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that management will be participating at two upcoming investor conferences. Meetings will be conducted at the JonesTrading 2023 Healthcare Summit, being held October 9-11 in Miami, FL, and at the 4th Annual Dawson James ...
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigare...
Achieve Life Sciences Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Phase 2 ORCA-V1 trial results will be presented at the Society for Research on Nicotine and Tobacco Europe...
Achieve Life Sciences Announces Participation at Upcoming Investor Con...
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences SEATTLE and VANCOUVER, British Columbia, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that John Bencich, CEO of Achieve, will be participating at three upcoming conferences. H.C. Wainwright 25th Annual Global Investment ConferenceDate: Monday, September 11, 2023Event: On-demand PresentationTime: 7:00 AM ...
Achieve Life Sciences Reports Financial Results for Second Quarter 202...
Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE and VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highl...
Achieve Life Sciences to Announce Second Quarter 2023 Financial Result...
Achieve Life Sciences to Announce Second Quarter 2023 Financial Results and Host Conference Call and Webcast SEATTLE and VANCOUVER, British Columbia, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its second quarter 2023 financial results on Monday, August 14, 2023, and host a conference call and webcast on Tuesday, August 15, 2023, at 8:30 AM EDT. To access the ...
Achieve Life Sciences Announces Presentation at 2023 American Society ...
Achieve Life Sciences Announces Presentation at 2023 American Society of Pharmacognosy Annual Meeting SEATTLE and VANCOUVER, British Columbia, July 18, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced participation on a panel during the 2023 American Society of Pharmacognosy (ASP) Annual Meeting, being held at the Bethesda North Marriott Hotel Conference Center in Rockville, MD from July 22-26, 202...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.